NCT06056297: An ongoing trial by X4 Pharmaceuticals
This trial is ongoing. It must report results 2 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06056297 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 6, 2024 |
| Completion date | Sept. 30, 2027 |
| Required reporting date | Sept. 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |